CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
Site Search
Showing 1 - 4 of 4 results
News
|
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
News
|
|
3 min read
This year’s program marked the largest in-person advocacy event in the Foundation’s history.
News
|
|
3 min read
Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.
News
|
|
5 min read